CJC-1295: long-acting growth hormone releaser

What this is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the natural pituitary-signaling hormone that tells the brain's master gland to release growth hormone. It was created by ConjuChem Biotechnologies in Montreal in the early 2000s, building on the GHRH(1–29) fragment first characterized at the Salk Institute in the 1980s. ConjuChem's key innovation was a technology called the Drug Affinity Complex (DAC): a reactive linker added to the peptide that covalently binds circulating serum albumin after injection, turning the short-lived peptide into a long-lasting depot. The result is a compound whose half-life extends from minutes (native GHRH) to approximately 6–8 days, enabling infrequent dosing (Jetté and colleagues 2005; Ionescu and colleagues 2006).

CJC-1295 exists in two pharmacologically distinct forms. The DAC-containing version (CJC-1295 DAC) has the albumin-binding linker and produces sustained GHRH-receptor stimulation over days from a single dose. The no-DAC version — also sold as Modified GRF 1–29 — retains the four protease-resistance amino acid substitutions but lacks the albumin linker, giving it a half-life of roughly 30 minutes and a discrete-pulse pharmacology more similar to endogenous GHRH. The two forms are not interchangeable. The stored sequence (YADAIFTNSYRKVLGQLSARKLLQDIMSR) represents the native GHRH(1–29) backbone; the active CJC-1295 molecule carries substitutions at positions 2, 8, 15, and 27, and the DAC form additionally bears the maleimidopropionic acid linker at the C-terminal lysine — neither modification is encoded in that raw sequence.

Neither form has been approved by any major regulatory authority. CJC-1295 is not an FDA-approved drug.

History

CJC-1295 was developed by ConjuChem Biotechnologies in the early 2000s as part of a program to extend the pharmacokinetics of therapeutic peptides. The GHRH(1–29) backbone traces to foundational work from the Salk Institute in the 1980s that established which fragment of the 44-residue native hormone was sufficient for receptor activation. ConjuChem's contribution was twofold: four amino acid substitutions (D-Ala at position 2, Gln at position 8, Ala at position 15, Leu at position 27) that confer resistance to degradation by the enzyme DPP-IV, and the DAC maleimidopropionic acid linker that forms a covalent bond with cysteine-34 on serum albumin after injection (Jetté and colleagues 2005). The albumin-binding chemistry was central to ConjuChem's identity as a biotech — the same Drug Affinity Complex platform had been applied to other peptide programs before CJC-1295.

ConjuChem advanced the DAC form through Phase I dose-escalation trials in healthy adults (Teichman and colleagues 2006) and into a Phase II program in HIV-associated lipodystrophy. The Phase II program was discontinued after a patient death; the attending physician concluded that the death was unrelated to CJC-1295 administration, but the program was not continued and no Phase II results were published. ConjuChem subsequently wound down operations in the early 2010s. CJC-1295 was never approved by any regulatory authority and migrated into research-chemical and compounding-pharmacy channels, where it has remained widely circulated despite the absence of a completed clinical program.

The "CJC" initialism refers to ConjuChem; the DAC suffix distinguishes the albumin-binding version from Modified GRF 1–29, which lacks the linker.

What it does

CJC-1295 stimulates the pituitary gland to release growth hormone (GH). In healthy adults given a single subcutaneous dose of the DAC form, GH levels rose 2- to 10-fold over baseline and remained elevated for six days or more; IGF-1 — the liver-derived downstream hormone that mediates most of GH's anabolic and lipolytic effects — rose 1.5- to 3-fold and remained elevated for 9–11 days. After multiple doses, IGF-1 elevation was sustained for up to 28 days (Teichman and colleagues 2006). A separate pharmacodynamic study confirmed that GH pulse amplitude was approximately 7.5-fold above baseline during CJC-1295 stimulation, and that pulsatile GH secretion continued to occur rather than being replaced by flat, continuous GH elevation (Ionescu and colleagues 2006).

Because CJC-1295 acts upstream of GH rather than supplying GH directly, the negative-feedback loop remains intact: somatostatin released in response to rising GH and IGF-1 levels can still modulate pituitary activity. This is pharmacologically distinct from injecting recombinant human GH, which bypasses pituitary regulation entirely.

Animal work showed that once-daily CJC-1295 normalized growth in GHRH-knockout mice, confirming the mechanism is GHRH-receptor-dependent and capable of supporting growth when endogenous GHRH is absent (Ionescu and colleagues 2006).

Evidence

• Human: Phase I dose-escalation trial in 43 healthy adults demonstrated dose-dependent, sustained GH and IGF-1 elevation from a single subcutaneous injection of CJC-1295 DAC (Teichman and colleagues 2006). A separate pharmacodynamic study confirmed 7.5-fold GH pulse amplitude increase with preservation of pulsatile GH secretion (Ionescu and colleagues 2006). A Phase II program in HIV-associated lipodystrophy was discontinued after a patient death and no results were published; no Phase III data exist. The entire published human evidence base originates from the single ConjuChem development program and has not been independently replicated.
• Animal: Growth normalization in GHRH-knockout mice; pharmacokinetic characterization of DAC-form albumin binding; receptor-engagement studies in rat anterior pituitary cells (Jetté and colleagues 2005).
• In vitro: Receptor binding activity and DPP-IV resistance of DAC conjugates confirmed in cultured rat anterior pituitary cells (Jetté and colleagues 2005).

Known effects

• Sustained GH elevation in healthy adults — Phase I human evidence; DAC form only; 2–10-fold increase lasting ≥6 days in a single-dose study (Teichman and colleagues 2006)
• Sustained IGF-1 elevation in healthy adults — Phase I human evidence; 1.5–3-fold increase for 9–11 days single-dose; up to 28 days with multiple doses (Teichman and colleagues 2006)
• Preserved GH pulsatility — Phase I pharmacodynamic evidence; pulses persist during continuous receptor stimulation (Ionescu and colleagues 2006)
• Growth normalization in GH-deficient animals — Preclinical; GHRH-knockout mouse model
• Serum protein profile changes — GH/IGF-1 axis activation produces measurable changes in serum protein composition in normal adult subjects (Ionescu and colleagues, Growth Hormone & IGF Research 2009)
• Body composition, recovery, sleep quality — No controlled human efficacy data exist for these endpoints; effect claims in these domains are anecdotal and community-reported, not derived from published clinical trials

Safety signals

Signals identified in available published literature:

• Flushing — Described as common in Phase I human trial and clinical sources; related to GHRH pathway activation; typically mild and transient
• Injection-site reactions — Mild to moderate; described in Phase I human trial
• Fluid retention / peripheral edema — Dose-dependent; more pronounced at higher doses and with the DAC form; described in clinical and community sources
• Mild headache — Occasional; most commonly reported with early doses
• Drowsiness or fatigue in first week — Noted in available clinical and community-use literature
• Insulin counter-regulation — GH opposes insulin action; sustained GH and IGF-1 elevation from the DAC form may affect glycemic control; flagged as a theoretical concern in available sources
• Theoretical IGF-1-mediated cancer promotion — Shared class-level concern for all GH-raising compounds; not addressed by any clinical cancer-incidence endpoint study in available literature
• Patient death in Phase II program — One death was reported during the discontinued Phase II HIV-lipodystrophy trial; the attending physician adjudicated the death as unrelated to CJC-1295; the program was not published and independent causation review is not available from the literature

Long-term human safety data (beyond 28–49 days) are absent from the published evidence base. Whether sustained IGF-1 elevation carries the same theoretical cancer-promotion risk as exogenous recombinant GH is unresolved. Pituitary desensitization from chronic GHRH-receptor occupancy is a theoretical concern not addressed in any long-duration human study.

Regulatory status

• US (FDA): Not approved for any indication. Classified as an investigational compound. FDA 503A compounding guidance has restricted commercial compounding of CJC-1295; widely circulated in research-chemical channels, which are not authorized for human use.
• EU (EMA): Not authorized.
• UK (MHRA): Not authorized.
• Australia (TGA): GHRH analogs and GH secretagogues are classified as Schedule 4 prescription-only substances; enforcement against unapproved sales reported in available sources.
• Canada: Treated as an unapproved investigational agent, analogous to the US position.
• WADA: Prohibited at all times under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Validated LC-MS/MS and immuno-PCR detection methods for CJC-1295 have been published (Guddat and colleagues; Baumgärtel and colleagues); athlete positive tests have been documented in the antidoping literature. Equine detection windows of up to eight days post-administration have been reported in population studies.

Myths and misconceptions

• "CJC-1295 is safe because it uses your body's own pathways." The pulsatile-preservation argument is real — feedback loops stay intact and side effects like edema and carpal tunnel are typically milder than with flat exogenous recombinant GH. But the downstream mediator is the same: IGF-1. The theoretical cancer-promotion concerns that attach to any sustained IGF-1 elevation attach here too. "Safer in degree" does not mean "safe in kind."

• "CJC-1295 DAC and no-DAC are the same drug at different doses." They are different molecules with different pharmacology. The DAC form has a maleimidopropionic acid linker covalently binding serum albumin, producing a half-life of approximately 6–8 days and sustained receptor engagement. The no-DAC form (Modified GRF 1–29) lacks this linker and clears in roughly 30 minutes, producing discrete GH pulses. Dosing cadence, receptor-engagement duration, and GH secretion profiles differ materially.

• "CJC-1295 had a pharmaceutical sponsor so it must be approved." ConjuChem advanced it to Phase II, but the Phase II program was discontinued and the compound was never approved by any major regulatory authority. Reaching Phase II is not FDA approval, and no licensed drug exists.

• "CJC-1295 is undetectable in drug testing." Published antidoping research has established LC-MS/MS and immuno-PCR detection methods specifically for CJC-1295 and related GHRH analogs. Equine studies show detection for up to eight days post-administration, and athlete positive tests have been documented.

Mechanism

CJC-1295 is a GHRH-receptor agonist. The GHRH receptor (GHRHR) is a class B G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. Binding of CJC-1295 to GHRHR activates adenylyl cyclase, raising intracellular cAMP levels and engaging the PKA signaling cascade that promotes GH gene transcription and GH secretion. Downstream, GH acts on liver, adipose tissue, and muscle; hepatic GH-receptor activation drives IGF-1 synthesis, the principal mediator of GH's anabolic and lipolytic effects.

The four amino acid substitutions relative to native GHRH(1–29) — D-Ala at position 2, Gln at position 8, Ala at position 15, Leu at position 27 — confer resistance to enzymatic degradation, particularly cleavage by DPP-IV, without substantially altering receptor binding affinity (Jetté and colleagues 2005). These substitutions extend the pharmacologically active lifetime of the free (non-albumin-bound) peptide.

The DAC form adds a maleimidopropionic acid linker at the C-terminal lysine that reacts with cysteine-34 on circulating serum albumin in vivo, forming a covalent conjugate. Albumin's long plasma half-life (~19 days) acts as a circulating depot, slowly releasing active CJC-1295 and sustaining GHRHR activation for approximately 6–8 days per dose (Jetté and colleagues 2005; Ionescu and colleagues 2006). This sustained engagement means CJC-1295 DAC itself does not produce pulsatile signaling — but intrinsic pituitary rhythm and the independent ghrelin/GHS-R1a axis continue operating, so GH pulses still occur, as confirmed in human pharmacodynamic studies (Ionescu and colleagues 2006).

The no-DAC form (Modified GRF 1–29) lacks the albumin linker. It clears in approximately 30 minutes and produces discrete-pulse GHRHR engagement more closely mimicking endogenous GHRH pulsatility.

Open questions

• Long-term human safety: Phase I data covers 28–49 days in healthy adults. No chronic human safety data exist. Whether sustained IGF-1 elevation from the DAC form carries the same theoretical cancer-promotion risk as exogenous recombinant GH — or whether the preserved-feedback argument translates into a materially different risk ceiling — is not resolved.

• Phase II outcome ambiguity: The discontinued Phase II HIV-lipodystrophy trial was never published. The attending physician's adjudication that the patient death was unrelated to CJC-1295 is not independently reviewable from available literature. The nature of the safety signal is not fully characterized in the public record.

• No-DAC human efficacy gap: Both published human pharmacodynamic studies tested only the DAC form. No equivalent controlled human efficacy data exist for Modified GRF 1–29, despite community and clinical use having shifted substantially toward the no-DAC version.

• Independent replication: The entire published human evidence base originates from a single development program (ConjuChem, mid-2000s). No independently sponsored human replication of the Phase I findings is described in available literature.

• Pituitary desensitization: Whether sustained GHRHR occupancy from chronic DAC-form use downregulates receptor responsiveness over time is not addressed by any long-duration human study.

• Combination with GHRPs: CJC-1295 paired with a growth hormone-releasing peptide such as ipamorelin is the dominant reported community-use pattern, but no controlled human endpoint trial testing this combination appears in available literature. The synergistic rationale is pharmacological and mechanistic rather than clinical-endpoint-based.

• Cardiovascular endpoints: Chronic effects of secretagogue-driven GH/IGF-1 elevation on cardiac mass, fluid balance, and cardiovascular risk have not been characterized in dedicated endpoint trials.

Related peptides

• Sermorelin — native GHRH(1–29) amide; shorter half-life than CJC-1295 DAC; the approved clinical comparator for GH deficiency testing
• Tesamorelin — another modified GHRH(1–29) analog; FDA-approved for HIV-associated lipodystrophy; the most clinically validated GHRH analog; shares the modified GRF backbone lineage with CJC-1295
• Ipamorelin — a selective GHRP acting via the ghrelin/GHS-R1a receptor; frequently discussed alongside CJC-1295 as a complementary GH-secretagogue pairing